Sultan Qaboos University, Oman
Sulaiman Al-Hashmi received his Ph.D. degree from KarolinskaInstitutet in 2011. He is managing the National Tissue Typing Laboratory in Sultanate of Oman. Dr. Al-Hashmi current work is focused on the use of MSC on tissue repair and regenerative medicine. He has published several papers in peer reviewed journals.
The use of hematopoietic stem cell transplantation (HSCT) is continuously expanding to cover a broader range of diseases. Because HSCT implicates the immune system, the new cells from the donor cannot be engrafted without compromising the recipient immune system. Currently, approximately 50 % of patients undergoing HSCT are conditioned with chemotherapy. Although the chemotherapeutic regimens have improved the outcomes of transplanted or cancer patients they have been associated with severe side effects that can considerably compromise the quality of patients’ life. Recent studies have shown that even short-term chemotherapy can cause vascular injury that leads to potential adverse cardiac effects, including heart failure and hypertension. Mesenchymal stem cells (MSC) therapy could be a promising procedure to reduce vascular damage and increase tissue repair as these cells are endowed with a potent tissue regeneration capacity along with immunosuppressive properties. MSC therapy can decrease cardiotoxicity and improve vascular repair following chemotherapy regimens. Additionally, MSC infusion can influence the function of the endothelial cells and the level of the growth factors, inflammatory cytokines and immune cells. Collectively, understanding of MSC as a pharmacological tool to repair vascular damage and other organ dysfunction following chemotherapy in HSCT or cancer patients is of paramount importance to develop effective protocols.
Speaker PPTsDownload PPT